Inflammaging: How Chronic Inflammation Drives Aging and What to Do About It

Inflammaging: Chronic Inflammation and Aging is not a buzzword. It is a clinically observed phenomenon where low-grade, persistent inflammation accelerates the biological processes we associate with getting older. Understanding this connection matters because it shifts the conversation from simply treating age-related diseases to potentially slowing the inflammatory drivers that precede them.

What the Research Actually Shows

The evidence for inflammaging comes from multiple lines of research. Epidemiological studies consistently show that older adults with elevated inflammatory markers—C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α)—have higher rates of cardiovascular disease, cognitive decline, and metabolic dysfunction. These are associations, not proof of causation, but they are robust and reproducible across populations.

Randomized controlled trials targeting inflammatory pathways have produced mixed but instructive results. Caloric restriction and exercise reliably lower inflammatory markers in older adults. Specific supplements show more variable outcomes, which we will examine in detail.

Where human data is limited, animal studies have been pivotal. Researchers have demonstrated that reducing systemic inflammation in aged mice improves tissue function across multiple organs. However, translation to humans remains uncertain. The gap between rodent models and human biology is substantial, and we should treat preclinical findings as hypothesis-generating rather than conclusive.

The Mechanism: How Inflammation Ages Cells

At the cellular level, inflammaging operates through several interconnected pathways. The most prominent involves the nuclear factor-kappa B (NF-κB) signaling cascade. In aging cells, NF-κB becomes chronically activated, driving the expression of pro-inflammatory genes that would normally be tightly regulated.

A second critical mechanism involves cellular senescence. Senescent cells accumulate with age and secrete a cocktail of inflammatory molecules collectively termed the senescence-associated secretory phenotype (SASP). These cells do not divide, but they are metabolically active—and destructive to their surrounding tissue environment. The SASP creates a feed-forward loop: inflammation promotes senescence, and senescent cells promote more inflammation.

Mitochondrial dysfunction plays a central role. Aging mitochondria produce excess reactive oxygen species (ROS), which damage cellular components and trigger inflammatory responses. Gomes et al. (2013) demonstrated that declining NAD+ levels disrupt nuclear-mitochondrial communication during aging, creating what they termed a "pseudohypoxic state." This metabolic disruption impairs mitochondrial function and exacerbates oxidative stress, further fueling inflammatory signaling.

The NAD+ connection is particularly relevant because it links energy metabolism to inflammatory control. NAD+ is a cofactor for sirtuins, a family of enzymes that regulate inflammation, DNA repair, and mitochondrial biogenesis. As NAD+ declines with age—by some estimates, to roughly half of youthful levels—sirtuin activity falls and inflammatory pathways become less constrained.

NMN and the NAD+–Inflammation Axis

Nicotinamide mononucleotide (NMN) is a direct precursor to NAD+. The rationale for NMN supplementation is straightforward: restore NAD+ levels, reactivate sirtuins, and thereby dampen the inflammatory signaling that characterizes inflammaging. The clinical evidence is still emerging, but several human trials provide relevant data.

Study	Population	Dose & Duration	Key Findings
Yoshino et al. (2021)	Prediabetic women (n=25)	250 mg/day, 10 weeks	Improved muscle insulin sensitivity; no significant inflammatory markers reported
Igarashi et al. (2022)	Healthy older men (n=21)	250 mg/day, 12 weeks	Elevated blood NAD+ levels; altered muscle function; inflammatory outcomes not primary endpoint
Irie et al. (2020)	Healthy Japanese men (n=10)	100–500 mg/day, single and multiple doses	Well-tolerated; dose-dependent increase in NMN metabolites; no adverse effects reported
Liao et al. (2021)	Amateur runners (n=48)	300–1200 mg/day, 6 weeks	Enhanced aerobic capacity in dose-dependent manner; exercise recovery improved
Niu et al. (2023)	Pre-aging adults (n=30)	300 mg/day, 60 days	Changes in serum metabolism and fecal microbiota; telomere length effects observed

The table reveals a consistent pattern: NMN reliably raises NAD+ levels and produces measurable physiological effects, but direct anti-inflammatory endpoints have not been the primary focus of most trials. Yoshino et al. (2021) demonstrated improved insulin sensitivity, which is mechanistically linked to reduced inflammation, though inflammatory markers were not explicitly measured. Igarashi et al. (2022) confirmed NAD+ elevation in older men but did not report inflammatory outcomes as a primary endpoint.

Niu et al. (2023) is notable for examining metabolic and microbiome changes in a pre-aging population, with telomere length as an exploratory measure. The metabolic shifts observed suggest systemic effects that could influence inflammatory status, though the study was not powered for definitive conclusions.

For those considering NMN, dose and form matter. The studies above used doses ranging from 250 mg to 1200 mg daily, with 250–500 mg being the most commonly tested range. Bio:sudo NMN 1000mg provides a dose at the higher end of the studied spectrum, which may be relevant for individuals seeking to replicate the higher-dose arms of trials like Liao et al. (2021).

It is worth noting that no long-term safety data beyond 12 weeks exists in peer-reviewed literature. Irie et al. (2020) established short-term safety across a dose range, but the absence of multi-year human trials means we cannot rule out rare or delayed adverse effects.

What the Evidence Does Not Show

Honesty about limitations is essential. No human study has demonstrated that NMN supplementation reduces mortality, prevents specific age-related diseases, or reverses established inflammatory conditions. The improvements in insulin sensitivity, aerobic capacity, and muscle function are meaningful but modest in magnitude.

The connection between NAD+ repletion and direct anti-inflammatory effects remains largely theoretical in humans. Animal studies show promising results—NMN reduces inflammatory markers in aged mice—but these findings have not been replicated in large, placebo-controlled human trials with inflammatory endpoints as primary outcomes.

Additionally, the microbiome findings from Niu et al. (2023) introduce complexity. NMN altered fecal microbiota composition, which could influence systemic inflammation through the gut-immune axis. However, we do not yet know whether these changes are beneficial, neutral, or potentially problematic in specific individuals.

Who Benefits Most

The evidence is strongest for specific populations. Middle-aged and older adults with declining metabolic function appear to be the most responsive group. Yoshino et al. (2021) focused on prediabetic women and found meaningful improvements in insulin sensitivity—a population where metabolic inflammation is typically elevated.

Physically active older adults may also see benefits. Igarashi et al. (2022) and Liao et al. (2021) both studied populations with some degree of physical activity and found measurable changes in muscle function and aerobic capacity. The Liao study's dose-response effect suggests that individuals engaged in regular training may benefit from higher NMN doses.

Those in the "pre-aging phase"—roughly 40 to 60 years old—are of particular interest given Niu et al. (2023). This is the window where NAD+ decline accelerates and inflammatory markers begin their upward trajectory, potentially making intervention most impactful.

Individuals already following anti-inflammatory lifestyle practices—regular exercise, adequate sleep, Mediterranean-style diet—may get the most from NMN supplementation. Supplements work best as adjuncts to foundational behaviors, not replacements for them. Related reading: NMN and Inflammation and Healthy Aging After 40.

Practical Takeaways

• Address lifestyle first. Exercise, sleep, and diet reduce inflammatory markers more reliably than any supplement. NMN should be viewed as an adjunct, not a substitute.
• Dose matters, but more is not definitively better. The 250–500 mg range has the most human safety data. Higher doses up to 1200 mg have been tested with benefits, but long-term safety is unknown.
• Expect metabolic, not miraculous, effects. The evidence supports improved insulin sensitivity, aerobic capacity, and muscle function—not reversal of aging or disease prevention.
• Consider your baseline. Those with prediabetes, declining exercise capacity, or early signs of metabolic dysfunction have the strongest rationale based on current trials.
• Monitor for individual response. NMN is generally well-tolerated, but personal biochemistry varies. Pay attention to sleep, energy, and exercise recovery as informal markers.
• Stay updated. This field moves quickly. Trials with explicit inflammatory endpoints in larger populations are needed before stronger claims can be made.

Bottom Line

Inflammaging is a real biological phenomenon with solid mechanistic grounding, but our ability to intervene pharmacologically remains limited. NMN raises NAD+ levels reliably in humans and produces measurable metabolic benefits, yet direct evidence for anti-inflammatory effects in people is still emerging. The supplement is a reasonable consideration for middle-aged and older adults focused on metabolic health, provided expectations remain grounded in what the current evidence actually shows.

References

1. Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224–1229. [Source]
2. Igarashi M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men." npj Aging. 2022;8(1):5. [Source]
3. Irie J, et al. "Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men." Endocrine Journal. 2020;67(2):153–160. [Source]
4. Liao B, et al. "Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study." Journal of the International Society of Sports Nutrition. 2021;18(1):54. [Source]
5. Gomes AP, et al. "Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell. 2013;155(7):1624–1638. [Source]
6. Niu KM, et al. "The impacts of short-term NMN supplementation on serum metabolism, fecal microbiota, and telomere length in pre-aging phase." Nutrients. 2023;15(3):755. [Source]

---

---